|Other Names||Nostrin, BM247 homolog, Nitric oxide synthase traffic inducer, Nitric oxide synthase trafficker, eNOS-trafficking inducer, NOSTRIN|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13833c was selected from the Center region of NOSTRIN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Multivalent adapter protein which may decrease NOS3 activity by inducing its translocation away from the plasma membrane.|
|Cellular Location||Isoform 1: Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasmic vesicle Cytoplasm, cytoskeleton. Note=Enriched in selected actin structures|
|Tissue Location||Expressed at highest levels in heart, kidney, placenta and lung, and at lowest levels in brain, thymus and spleen. Present in vascular endothelial cells and placenta. Over- expressed in placenta from women with pre-eclampsia (at protein level).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Nitric oxide (NO) is a potent mediator in biologicprocesses such as neurotransmission, inflammatory response, andvascular homeostasis. NOSTRIN binds the enzyme responsible for NOproduction, endothelial NO synthase (ENOS; MIM 163729), andtriggers the translocation of ENOS from the plasma membrane tovesicle-like subcellular structures, thereby attenuatingENOS-dependent NO production.
Holt, R., et al. Eur. J. Hum. Genet. 18(9):1013-1019(2010)Maestrini, E., et al. Mol. Psychiatry 15(9):954-968(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Wiesenthal, A., et al. Traffic 10(1):26-34(2009)Schilling, K., et al. Mol. Biol. Cell 17(9):3870-3880(2006)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.